BioSpace News Archive

Kezar Life Sciences, Inc., a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, announced the appointment of Gitanjali Jain as Vice President, Investor Relations and External Affairs.

Oncternal Therapeutics, Inc. announced pre-clinical data from ONCT-534, an androgen receptor N-terminal-domain-binding small molecule degrader, was accepted for virtual poster presentation at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics on October 7-10, 2021.

Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), announced an upcoming presentation on AT-1501, its lead clinical candidate, at the International Pancreas and Islet Transplantation Association (IPITA) Congress, which is being held virtually from October 20-23, 2021.

Lutris Pharma today announced that, based on the compelling results observed in part one, it has initiated part two of its phase 1/2 trial of lead compound, LUT014, a topically applied, novel B-Raf inhibitor, for the treatment of radiation-induced dermatitis (RD) in breast cancer patients.

Can-Fite to Present at H.C. Wainwright 5 th Annual NASH Investor Conference on October 12, 2021

Gemini Therapeutics, Inc. today announced a corporate restructuring, including several executive officer transitions, to prioritize assets and focus on initiating and executing GEM103’s resource-intensive pivotal trial in geographic atrophy (GA).

Enanta Pharmaceuticals to Present at the H.C. Wainwright 2nd Annual Hepatitis B Virus Virtual Conference

AVROBIO, Inc. today announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 201,750 shares of the company’s common stock to eight new employees as inducement awards under the company’s 2019 Inducement Plan.

Statera Biopharma, Inc. today announced that Michael K. Handley, President and Chief Executive Officer, has been invited to participate as an expert speaker during the 2nd Annual B & T Cell-Mediated Autoimmune Disease Drug Development Summit.

Harpoon Therapeutics, Inc. today announced that an abstract with preclinical data of its TriTAC-XR T cell engager platform has been accepted for poster presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).